Shareholder Class Action Filed Against Sequenom, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & ...(t its financial well-being and future bu...),Health

On April 29, 2009, the Company astounded its investors and the market when it announced that the launch of SEQureDx would be delayed due to the discovery by Company officials of employee mishandling of research and development ("R&D") test data and results. As a result, the Company announced that its statements made between June 4, 2008 and February 3, 2009 regarding SEQureDx should no longer be relied upon. Following this announcement, it became apparent that the Company would be unable to launch SEQureDx in 2009, as originally planned. Further, the Company indicated that it would wait for results from independent clinical trials before launching the test, rather than relying on its own research. Upon the release of this news, shares of the Company's stock fell an astounding $11.29 per share, or 75.72 percent, to close on April 30, 2009 at $3.62 per share, on unusually heavy trading volume.

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Barroway Topaz Kessler Meltzer & Check which prosecutes class actions in both state and federal courts throughout the country. Barroway Topaz Kessler Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Barroway Topaz Kessler Meltzer & Check, or for additional information about participating in this action, please visit www.btkmc.com.

If you are a member of the class described above, you may, not later than June 30, 2009, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf
'/>"/>